“Intellia Stock Could Surge 35-45% After Positive Gene Editing Data, Says Analyst”
June 28, 2021
“On Saturday, the company released interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder… While it is still early days, Issi calls the data a “major de-risking event for the platform,” and sees the shares surging by 35-45% on the news… All in all, the analyst reiterated an Outperform (i.e., Buy) for NTLA shares, backed by a $110 price target. There’s upside of 24% from current levels…”
https://finance.yahoo.com/news/intellia-therapeutics-interim-phase-1-112530583.html